Prevention of Inflammatory Lung Injury After Chlorine Exposure
Prevention of Inflammatory Lung Injury After Chlorine Exposure
批准号:
7851307
负责人:
MICHAEL D GUNN
金额:
$40.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2012-05-31
关键词:
Bacterial InfectionsCellsChemical Warfare AgentsChlorineClinical TrialsDendritic CellsDoseEndotoxinsEpithelialEventExudateHumanImmuneInflammationInflammation MediatorsInflammatoryInfluenzaInjuryLaboratoriesLeadLeukocytesLungMediatingMediator of activation proteinMorbidity - disease rateMucous MembraneMusPathologyPatternPermeabilityPharmaceutical PreparationsPhase I Clinical TrialsPhysiologicalPneumoniaPreventionReactionRelative (related person)Research PersonnelSeriesSourceStructure of parenchyma of lungT-LymphocyteTestingToxic effectViralWorkbasecell motilitycell typechemokine receptorchlorine gaslung injurymacrophagemigrationmonocytemortalityneutrophiloxidative damagepreventprogramsresponsesmall molecule
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Chlorine gas (CI2) is a readily available chemical warfare agent that causes a dose-dependent toxicity to pulmonary and other mucosal tissues. The major toxicity of CI2 exposure is oxidative damage of lung tissues that is thought to be due to the direct effects of CI2 reaction products combined with inflammatory mediators released by lung-infiltrating leukocytes. This proposed mechanism has not been clearly demonstrated but raises the possibility that inhibition of pulmonary inflammation following CI2 exposure will reduce subsequent morbidity and mortality. Our laboratory has identified the cells and the cell migration events that lead to immune-mediated lung damage, morbidity, and mortality during viral and bacterial infections. Our preliminary studies demonstrate that a similar pattern of inflammation occurs after chlorine exposure. These findings suggest that chlorine-induced lung injury could be substantially lessened using a specific chemokine receptor antagonist. Importantly, a pharmacologic antagonist for the chemokine receptor we have identified has already been developed and proven to be safe and effective in early clinical trials for other indications. This raises the possibility that a drug already exists that would reduce the morbidity and mortality of chlorine exposure in humans. In a series of murine studies, we will determine the extent to which specific pulmonary inflammatory cell types contribute to chlorine-induced lung injury and the consequent epithelial damage, bronchial reactivity, morbidity, and mortality. We will then examine the ability of the chemokine receptor antagonist to reduce these toxicities. These studies will provide a basis for determining if trials of chemokine receptor antagonists should be considered in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of point-of-care testing for Lassa and other hemorrhagic fever arenaviruses
-
批准号:10656548
-
项目类别:
-
资助金额:$39.7万
-
财政年份:2022
-
负责人:MICHAEL D GUNN
-
依托单位:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
-
批准号:10092930
-
项目类别:
-
资助金额:$19.73万
-
财政年份:2020
-
负责人:MICHAEL D GUNN
-
依托单位:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
-
批准号:9896170
-
项目类别:
-
资助金额:$23.77万
-
财政年份:2020
-
负责人:MICHAEL D GUNN
-
依托单位:
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma
-
批准号:10246886
-
项目类别:
-
资助金额:$56.58万
-
财政年份:2018
-
负责人:MICHAEL D GUNN
-
依托单位:
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma
-
批准号:10477339
-
项目类别:
-
资助金额:$56.47万
-
财政年份:2018
-
负责人:MICHAEL D GUNN
-
依托单位:
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma
-
批准号:10006178
-
项目类别:
-
资助金额:$52.12万
-
财政年份:2018
-
负责人:MICHAEL D GUNN
-
依托单位:
Generation of Zika virus-specific recombinant antibodies
-
批准号:9226804
-
项目类别:
-
资助金额:$23.85万
-
财政年份:2016
-
负责人:MICHAEL D GUNN
-
依托单位:
Generation of Zika virus-specific recombinant antibodies
-
批准号:9331436
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2016
-
负责人:MICHAEL D GUNN
-
依托单位:
A novel cellular tumor vaccine strategy for mutant IDH1 glioma
-
批准号:10248330
-
项目类别:
-
资助金额:$16.09万
-
财政年份:2014
-
负责人:MICHAEL D GUNN
-
依托单位:
A novel cellular tumor vaccine strategy for mutant IDH1 glioma
-
批准号:10248318
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2014
-
负责人:MICHAEL D GUNN
-
依托单位:
A novel cellular tumor vaccine strategy for mutant IDH1 glioma
-
批准号:10705246
-
项目类别:
-
资助金额:$29.12万
-
财政年份:2014
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Salmonella Single-chain Abs as serum diagnostics
-
批准号:8468639
-
项目类别:
-
资助金额:$23.21万
-
财政年份:2012
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Salmonella Single-chain Abs as serum diagnostics
-
批准号:8871680
-
项目类别:
-
资助金额:$37.17万
-
财政年份:2012
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Salmonella Single-chain Abs as serum diagnostics
-
批准号:8839873
-
项目类别:
-
资助金额:$42.27万
-
财政年份:2012
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Salmonella Single-chain Abs as serum diagnostics
-
批准号:8302016
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2012
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics
-
批准号:7779310
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2010
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics
-
批准号:8413658
-
项目类别:
-
资助金额:$46.25万
-
财政年份:2010
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics
-
批准号:8434024
-
项目类别:
-
资助金额:$41.66万
-
财政年份:2010
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics
-
批准号:8607110
-
项目类别:
-
资助金额:$45.07万
-
财政年份:2010
-
负责人:MICHAEL D GUNN
-
依托单位:
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics
-
批准号:8008766
-
项目类别:
-
资助金额:$21.94万
-
财政年份:2010
-
负责人:MICHAEL D GUNN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: